GlassScriptPhysician profile
Jenna Spears
NPI 1023503141
$53,279.71
in general payments reported to CMS, 2019-2025
16 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2021: $47.71 · 2022: $329 · 2023: $2,615 · 2024: $736 · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $45K · Food and Beverage: $4,000 · Travel and Lodging: $3,038 · Education: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $45,000.00 |
| Food and Beverage | $4,000.04 |
| Travel and Lodging | $3,038.12 |
| Education | $661.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $30,893.27 | 2021-2025 | Assurity, Tacticath, Ensite |
| Medtronic, INC. | $16,729.51 | 2022-2025 | Advisa Dr Mri Surescan, Sphere-9, Affera Mapping System |
| Boston Scientific Corporation | $2,546.82 | 2021-2025 | General - Ep, Lux-Dx Insertable Cardiac Monitor, Versacross Access Solution |
| Biosense Webster, INC. | $1,581.47 | 2024-2025 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $411.79 | 2019-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.69 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $150.88 | 2019-2023 | Xarelto |
| Heartflow, INC. | $139.81 | 2023 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $137.73 | 2023-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $103.55 | 2023 | Verquvo |
| Cardiva Medical, INC. | $70.99 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Sanofi-Aventis U.S. LLC | $50.42 | 2023 | |
| Pfizer INC. | $29.82 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $29.31 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $22.96 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $19.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.